Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cutia TherapeuticsHKSE:02487 +3.73%42 PS Ratio is 2.28 as of Jul. 27, 2026, which is 75% below its 10-year median of 9.17. GuruFocus rates HKSE:02487 with a GF Score™ of 42/100 and a GF Value™ of HK$16.42 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 929 Biotechnology companies, Cutia Therapeutics ranks better than 82.78% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cutia Therapeutics's share price is HK$2.50.
Cutia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1.10. Hence, Cutia Therapeutics's PS Ratio for today is 2.28.
Good Sign:
Cutia Therapeutics stock PS Ratio (=2.15) is close to 5-year low of 2.15.
The historical rank and industry rank for Cutia Therapeutics's PS Ratio or its related term are showing as below:
HKSE:02487'
s PS Ratio Range Over the Past 10 Years
Min: 2.14 Med: 9.17 Max: 735.71
Current: 2.28
During the past 5 years, Cutia Therapeutics's highest PS Ratio was 735.71. The lowest was 2.14. And the median was 9.17.
HKSE:02487's PS Ratio is ranked better than 82.78% of 929
companies
in the Biotechnology industry
Industry Median: 9.03
vs HKSE:02487: 2.28
During the past 5 years, Cutia Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 395.30% per year. The lowest was 198.90% per year. And the median was 297.10% per year.
Back to Basics: PS Ratio
Cutia Therapeutics (HKSE:02487) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cutia Therapeutics PS Ratio Related Terms
Cutia Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Cutia Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02487 vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, Cutia Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cutia Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cutia Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cutia Therapeutics's Share Price of today is HK$2.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cutia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1.10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cutia Therapeutics (HKSE:02487) has a PS Ratio of 2.28 as of Jul. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cutia Therapeutics and its competitors. This is 75% below median its historical median of 9.17. Over the past decade, Cutia Therapeutics' PS Ratio has ranged from 2.14 to 735.71. According to the industry distribution chart, Cutia Therapeutics ranks #160 out of 929 companies in the Biotechnology industry, placing it in the top 17.2%.
Is Cutia Therapeutics' PS Ratio too high?
Cutia Therapeutics' current PS Ratio of 2.28 is 75% below median its 10-year median of 9.17. Over the past 10 years, this metric has ranged from a low of 2.14 to a high of 735.71. The Biotechnology industry median PS Ratio is 9.03. Cutia Therapeutics' value of 2.28 is 74.8% below this industry median. Based on the distribution chart, Cutia Therapeutics ranks #160 out of 929 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cutia Therapeutics has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cutia Therapeutics' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cutia Therapeutics ranks #160 out of 929 companies for PS Ratio. This places Cutia Therapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.03. Cutia Therapeutics' value of 2.28 is 74.8% below this benchmark. Historically, Cutia Therapeutics' own PS Ratio has ranged from 2.14 to 735.71 over the past decade. While the company's 10-year median is 9.17 vs. the industry median of 9.03, Cutia Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.03, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cutia Therapeutics's current PS Ratio of 2.28 is 74.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cutia Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cutia Therapeutics's current PS Ratio is 2.28, which is 75% below median its own 10-year median of 9.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cutia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cutia Therapeutics (HKSE:02487) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.42, compared to a current price of HK$2.50 — trading 84.8% below its estimated fair value. The current PS Ratio is 2.28, which is 75% below median its 10-year median of 9.17 and 74.8% below the Biotechnology industry median of 9.03. Cutia Therapeutics' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cutia Therapeutics (HKSE:02487), the current PS Ratio is 2.28 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cutia Therapeutics (HKSE:02487) Overvalued in 2026?
Based on GuruFocus' analysis, Cutia Therapeutics stock appears to be undervalued.
The current stock price of HK$2.50 is trading 84.8% below its estimated GF Value™ of HK$16.42.
GuruFocus considers Cutia Therapeutics to be Possible Value Trap.
Key valuation signals for HKSE:02487:
PS Ratio: 2.28 (75% below median its 10-year median of 9.17)
GF Value™: HK$16.42 vs. price of HK$2.50 (84.8% below fair value)
Industry Position: 74.8% below the Biotechnology median (#160 of 929)
No single metric tells the full story. See the HKSE:02487 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cutia Therapeutics is an investment holding company. The Company and its subsidiaries are principally engaged in developing inventive and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. It has a proprietary CATAME technology platform, which includes: Colloidal-Emulsification-Active Encapsulation (CEAE) platform, Aerosol (ARS) platform, Transdermal Delivery (TDD) platform, Actives & Formulation Evaluation (AFE) platform, Micro/Nano-Particulates & Self-Assembly (MiSA) platform, and Ex vivo & Efficacy Evaluation (EVEE) platform. It enables the development of a wide range of product dosage forms and the relevant formulation technology.
42GF Score
Get the complete analysis for HKSE:02487
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02487 has been successfully added to your 
